The current treatment is already licensed in adults, but is currently in a phase III trial for the treatment of multiple sclerosis in paediatric patients. Fingolimod will be administered orally once daily at a dose of either 0.5 mg or 0.25 mg depending on the patient’s body weight. If marketed this will become the first treatment with a specific licensed indication for paediatric multiple sclerosis.
Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years)
Interventions:
Fingolimod (Gilenya; FTY720; fingolimod hydrochloride)
Indications:
Multiple sclerosis (MS)
Therapeutic Areas:
Neurology
Year:
2017